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ABSTRACT 
Objectives: Foot orthoses are commonly prescribed as an intervention for people with rheumatoid 
arthritis. Data relating to the cost-effectiveness of foot orthoses in people with RA is limited. The aim 
was to evaluate the clinical and cost effectiveness of two foot orthoses in people with established 
RA. 
Methodology: A single-blind randomised controlled trial was undertaken to compare customised 
foot orthoses and simple insoles in 41 people with established RA. The Foot Function Index 
measured foot pain, disability and functional limitation. Costs were estimated from the perspective 
from the UK National Health Service, societal (patient and family) perspective and secondary care 
resource use in terms of the intervention and staff time.  Effects were assessed in terms of health 
gain expressed as quality adjusted life years (QALYS). 
Results: At baseline, 20 participants received the customised foot orthoses and 21 participants 
received a simple insole. After 16 weeks foot pain improved in the custom-made foot orthoses 
(p=0.000) and simple insoles (p<0.01). Custom-made foot orthoses improved disability scores 
(p<0.001) but not for simple insoles (p=0.40). The cost effectiveness results demonstrated no 
difference in cost between the arms (custom-made foot orthoses: £159.10; simple insole: £79.10 
p=0.35), with the customised foot orthoses being less effective in terms of cost per QALY gain 
(p<0.001).  
Conclusions: In people with established RA, semi-rigid customised foot orthoses can improve pain 
and disability scores in comparison to simple insoles. From a cost effectiveness perspective the 
customised foot orthoses were far more expensive to manufacture, with no significant cost per QALY 
gain.  
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INTRODUCTION 
Rheumatoid arthritis (RA) can lead to rapid development of joint damage and significant long-term 
disability [1]. Over 75% of people with RA report foot involvement within four years of diagnosis, 
and the reported prevalence of foot problems is between 50–90% [2]. Progressive joint destruction 
leads to varying degrees of physical disability with over 70% of all individuals with RA reporting 
moderate to severe foot pain, producing a significant clinical challenge and an international public 
health priority [3]. The National Institute for Clinical Effectiveness (NICE) reported the estimated 
annual cost of RA to be between £3.8 and £4.75 billion per year, including direct costs to the UK 
National Health Service (NHS) and other healthcare support agencies and indirect costs to the 
economy, including productivity losses and the personal impact on RA patients and their families [4]. 
 
Clinically effective management of foot pain and prevention of foot deformity are the chief goals of 
intervention for people with RA [5-7]. Non-pharmacological interventions for RA that include foot 
orthoses and footwear can reduce pain and disability and improve long-term outcomes with existing 
and potential foot problems [8]. Previous studies have reported on the clinical effectiveness of foot 
orthoses in people with established RA, ranging from simple insoles to customised foot orthoses [9-
12]. Clark [13] reported that few studies have undertaken a cost effectiveness analysis to investigate 
the cost implication of the prescription of foot orthoses for people with established RA, despite the 
high prevalence of foot involvement and the high direct cost of RA related health care to the UK 
economy. The issue of the cost effectiveness of providing foot orthoses in the UK National Health 
Service (NHS) has been raised in chronic musculoskeletal foot conditions [14], as it represents a 
considerable burden to patients, clinicians and health providers. However, data relating to cost-
effectiveness of the use of foot orthoses for people with RA are limited [15-17]. One UK study 
reported that foot orthoses should be replaced every 24 months, incurring low annual treatment 
costs as the FO unit used in the study cost £60 per pair [15]. In another UK study, Pallari [16] 
reported that RA patients paid on average £50 for customised foot orthoses using a digital three-
dimensional laser scanner. With such limited data the aim of this study was to evaluate the clinical 
and cost effectiveness of custom-made foot orthoses compared to simple insoles when prescribed 
for people with established RA. 
 
 
 
METHODOLOGY 
The research design was a single-blinded, exploratory randomised controlled clinical trial conducted 
over 16 weeks with participants randomly assigned to two intervention arms: custom-made foot 
orthoses (CMFO) or simple insoles (SI). The study design according to the CONSORT statement is 
demonstrated in Figure 1 [18]. Participants were recruited from a rheumatology outpatients 
department in the North-East of England, UK. Participants were eligible if they were over 18 years 
old, history of foot pain, ability to walk a required distance of 5m for measurement of foot function 
and had a diagnosis of RA according to the American College of Rheumatology/European League 
Against Rheumatism revised criteria [19]. Participants with a history of previous foot surgery or 
ulceration, those with an unstable medical regime or in a state of flare, currently using foot orthoses 
or unwilling to change their footwear to accommodate an orthotic, or with poor language ability or 
inability to understand the research protocol were excluded. Local ethical approval was obtained 
from Nursing and Professions Allied to Medicine Research Advisory Group, South Tees NHS Trust. All 
participants gave informed consent to participate in the study. The trial was registered with ANZCTR 
(ACTRN12615001252505). 
 
Sample size estimates for use in the study were calculated using sample size calculation tables [20]. 
For a large effect size (d) of 0.8, it was calculated that the trial would require 20 participants per arm 
to detect arm differences with 80% power. A plan for allocating to either intervention arms was 
independently generated using randomisation software available from St George’s Hospital Medical 
School website, http://www.sgul.ac.uk/depts/chs/chs_research/stat_guide/guide.cfm. Participants 
were recruited by the primary researcher and once baseline data had been collected the primary 
researcher contacted the independent investigator for arm allocation. Participants were blinded to 
the intervention. 
 
Participants were randomly allocated to receive either CMFO or SI. The CMFO were manufactured 
from high density ethyl vinyl acetate, with a thickness of 20mm and a shore density of 50, a 
contoured medial arch, high heel cup and external medial posting correction customised to each 
patient according to the amount of valgus rearfoot deformity present and maximum forefoot 
balancing technique, determined by the external manufacturer providing the interventions (Langer 
Biomechanics Arm, Cheadle, UK). Both foot orthoses were covered with 1.6mm cushioning material 
extending the length of the foot. The SIs were a simple 6mm cushioning insole made from a 
breathable foam core on a rubber-silicone-ethylene compound, cut to fit the exact shape of the 
participants’ footwear. Both interventions had the same colour for the covering in order to reduce 
the risk of bias. 
 
At the baseline visit age, sex, ethnicity, clinical characteristics and current pharmacological 
management were recorded.  Foot disease impact was measured using the Foot Function Index [21]. 
The Foot Function Index is a self-administered questionnaire consisting of 23-items armed in three 
domains: foot pain (nine items), disability (nine items) and functional limitation (five items). Higher 
scores suggest greater pain, disability and limitation of activity and thus poorer foot health [21].  
 
PROCEDURE 
A neutral suspension plaster of Paris cast was taken of participants’ feet to enable provision of the 
CMFO. Participants’ footwear was evaluated to ensure it was suitable to accommodate either type 
of foot orthoses. A template was taken to determine shoe size. To record weekly wear time and 
adverse events, which occurred during the 16-week study period, participants were issued with a 
self-reporting diary at the baseline study visit. 
 
We conducted a cost utility analyses which addresses health related quality of life.  NICE in England 
has recommended the use of quality-adjusted life years (QALYs) as the measure of health benefit for 
economic analysis as it allows comparisons across different clinical conditions, unlike condition 
specific quality of life measures [22].  We estimated direct costs from the NHS and from the 
participant perspective. We micro-costed NHS  secondary care resource  use in terms of the 
intervention and staff time spent with the participant  via a healthcare personal proforma completed 
at baseline and 16 weeks follow up. Costs to participants in terms of out of pocket expenses and 
travel costs were estimated by a health economics patient self-completed proforma at baseline and 
16 weeks. We derived unit costs of these sources from various sources [23] for podiatrists time (unit 
cost per minute for Band 5: 0.53). We obtained the costs of the foot orthoses (unit cost: £ 68.32) and 
the simple insole (unit cost of £24.82) to the NHS from Langer UK Ltd. Data collection was conducted 
between March 2008 and August 2010.  Out of pocket and travel expenses incurred by participants 
were inflated to 2015 prices using the retail price index [24].  
 
We estimated the effects on health related quality of life (utilities) of the interventions and 
undertook a cost-utility analysis using QALYs as the measure of effect.  We estimated participant 
utilities by administering the EQ5D instrument [25] at baseline and 16 weeks; combined them with 
the area under the curve method to calculate QALY gains over the 16 week study period; and 
corrected for baseline EQ5D.  We estimated the cost per QALY gain by dividing differences in cost by 
differences in QALYs and compared by the thresholds recommended by NICE [22].    
 
Data Analysis 
We analysed data in SPSS version 22.0 (SPSS Inc., Chicago II, USA) and MS Excel 2010 (Microsoft 
Corporation, Redmond, Washington DC, USA). Results were reported according to the CONSORT 
statement [26]. All descriptive data and health status measurements were obtained at baseline and 
16 weeks. All participant data was included in the final data analysis to ensure continuity of balance 
in both arms of the trial to reduce bias. All data was subjected to tests for accuracy and quality 
before analysis was undertaken. No transformation of data was undertaken.  Differences between 
the two arms were determined by analysis of covariance (ANCOVA), to assess the impact of the two 
different FO interventions on participants’ scores across the time periods of the trial. Where 
appropriate, as when dealing with categorical data, non-parametric tests such as Mann Whitney U 
tests were used. R (R-Foundation for Statistical Computing, Vienna, Austria) and Statistical Analysis 
Software (SAS Institute Inc) using the sub-heading Proc Mixed for the ANCOVA. Differences between 
and within arms were presented as mean differences and 90% confidence intervals (90%CI). This has 
been recommended as an appropriate confidence level and also as a way of discouraging 
reinterpretation of the 90%CI as significant or non-significant at the 5% level [27]. Because of the 
small numbers of participants in our trial we performed boot-strapped t-tests to estimate the 
differences between utilities at each of the time points and report means and standard deviations of 
the boot-strapped samples. To estimate effects on QALYS, we performed a linear regression with 
QALY gain as the dependent variable with treatment arm and baseline utility as independent 
variables. The level of statistical significance was set at 0.05. 
 
RESULTS 
One hundred and twenty potential participants were identified and forty-one were randomised. The 
majority of participants were females (n=28, 68%) with a mean (SD) age of 62 (10) years and a mean 
(SD) disease duration of 14 (9) years. All participants were receiving NSAIDS (n = 36, 88%) and 
DMARDS (n = 37, 90%). At baseline, 20 participants received the CMFO and 21 participants received 
the SI. At 16 weeks, 75% (n=15) of participants in the CMFO-arm and 66% (n= 14) participants in the 
SI-arm completed the study. Twelve participants (29%) withdrew over the course of the study 
(Figure 1).  
 
Table 1 demonstrates the descriptive statistics for the Foot Function Index domains. All participants 
wore their FOs when attending for review and reported wearing them in the week prior to review. 
The two interventions were worn on average 77 hours/week (CMFO-arm with an average of 87 
hours and the SI-arm an average of 67 hours). Three participants reported initial fit problems related 
to the thickness of the shoe insert, two withdrawing and one continuing within the trial after 
modifying footwear to increase the depth to accommodate the CMFO. No other adverse reactions 
were recorded. There was no difference between the two arms in wearing times over the 16 weeks 
(p=0.60). Table 2 demonstrates the differences between the sub-domains of the Foot Function Index 
from baseline to 16 weeks. The pain score reduced significantly in both intervention arms (p<0.000). 
The treatment effect of the intervention at 16 weeks was not significant between the two arms (p = 
0.14). The reduction in foot disability score was significant in the CMFO arm (p<0.000), but not in the 
SI arm (p =0.40). The treatment effect at 16 weeks did not reach significance (p = 0.12). The change 
in the activity limitation score did not reach significance in both arms (p<0.05).   
 
The effects of the interventions on health related quality of life (utility) and QALYs are shown in 
Table 3. At baseline there was a statistically insignificant difference between the arms of the trial.  
The difference in baseline utility was 0.10 in favour of the CFMO-arm.  The CFMO-arm showed a 
decrease in utility at 16 weeks compared to baseline whereas the SI-arm showed an increase.  When 
the area under the curve controlling for baseline utility method was applied, there was small 
statistically insignificant QALY loss associated with the CFMO intervention compared to SI. Therefore 
there no statistically significant effect of the intervention on QALYs was found. 
 
The amount of time spent for podiatric staff was similar for both interventions at baseline and 
follow-up time (Table 4).  Across the two-arms of the trial, the only significant difference in costs was 
that the CFMO being more expensive than the SI with a mean difference of £8.53 (bootstrapped 90% 
CI: £8.53 to £8.53). This lead to a statistically significant difference in total costs to the NHS with a 
mean difference of £8.90 (bootstrapped 90% CI: £5.02 to £13.27).  The mean costs of resource use 
over the 16 week follow-up period are illustrated in Table 5. The mean health gain, expressed as a 
difference in mean QALYs between interventions over the 16 week follow-up period, was -0.03 and 
the difference in mean cost to the NHS was £8.90.  From either costing perspective (NHS alone or 
NHS & patient), the CFMO was both more expensive and less effective than the SI and is therefore 
dominated.  
 
DISCUSSION 
NICE have suggested that interventions delivering a cost per QALY of under £20,000 are likely to be 
an acceptable use of NHS resources [4]. The current findings support the concept that foot orthoses 
for people with established RA delivers a cost-effective intervention. In both arms, from the societal 
perspective, patients’ costs were approximately equal and no further sensitivity analysis was 
undertaken. The cost per QALY gain results found in this study would suggest that the average cost 
per QALY gain is less than the NICE threshold and is therefore, an acceptable use of NHS resources. 
In comparison to other non-pharmacological interventions, one study on differences between 
shared care or nurse consultations compared to rheumatologists follow-up reported £7,800 per 
quality-adjusted life year [28]. In a study relating to exercises for hand function cost per quality-
adjusted life year was reported to be £9,549 [29]. In a recent systematic review on the cost-
effectiveness of biologics for the treatment of RA, Joensuu [30] reported the incremental cost-
effectiveness ratio of biologics ranged from £30,500 to £885,000/quality adjusted life year gained in 
comparison to conventional disease-modifying anti-rheumatic drugs.  
 
The main analysis was undertaken using only 16 weeks data, although it is likely that any benefits 
achieved within this period would be maintained for a longer period of time. It is plausible that 
changes in costs could have occurred over a longer time frame than the 16-week period, but this is 
an assumption without evidence therefore it was considered reasonable to assume equally 
distributed costs for this study. Both arms also only showed minimal improvement over the course 
of the study, but this may reflect a lack of sensitivity of the EQ5D to pick up subtle disease changes in 
the RA foot, which may have been masked by overall disease activity. 
 
We did find that pain scores improved significantly in both the arms, with a significant improvement 
in both the disability domain and total Foot Function Index scores for the CMFO-arm.  We found that 
there is a significant difference in cost between the two arms. The major difference in cost between 
the two arms maybe explained in terms of manufacturing time and costs of materials used in the 
manufacturing process with the CMFO costing significantly more to produce. However, the CMFO 
only produced some benefit in terms of patient outcomes. From a cost effectiveness analysis 
perspective the CMFO evaluated were far more expensive to manufacture, with the CMFO being 
£52.60 more expensive than the SI from an NHS perspective and £80.00 more expensive from an 
NHS and societal perspective. The CMFO may therefore be considered unlikely to be cost effective in 
comparison with the SI in the treatment of this cohort of RA patients of more than 2 years duration 
with foot pain, although still an acceptable use of healthcare resources overall. This does contrast 
with the cost-effectiveness study by Rome [14] which found that semi-rigid prefabricated foot 
orthoses resulted in a better quality of life for patients with plantar heel pain, despite being more 
expensive. It is, however, difficult to make any further comparisons with this study as the participant 
arm investigated was heterogeneous. The current study should therefore call into question the use 
of CMFO in preference to SIs in people with established RA, although further research would be 
needed to make any definitive recommendations. 
 
The current findings do present ramifications for health care professionals prescribing foot orthoses 
in people with established RA. A technology appraisal of foot orthoses has also not yet been 
undertaken by NICE, and although both interventions are likely to both deliver a cost per QALY of 
under £20,000 this finding does indicate that further research is necessary to support the 
prescription of foot orthoses in this cohort of patients as being  both cost and clinically effective.  
 
The sample size used for this study was based upon tables published in 2005 [20] which limits 
validity as modelling was unable to be undertaken as a result. However, there is currently limited 
economic studies to draw upon in foot orthoses evidence which can knowledgably inform public 
health policy either locally or nationally.  The current study relates to people with established RA, 
therefore future work could include cost effectiveness studies evaluating to the use of foot orthoses 
with early RA or in other inflammatory conditions. The current study was also undertaken using 
participants from the North-East of England, and therefore cannot be generalizable to all people 
with established RA. This study looked at the cost analysis of CMFO and SI and did not consider 
prefabricated foot orthoses. A larger clinical trial could be undertaken to investigate the cost 
effectiveness of simple insoles in people with established RA and further investigation into the cost 
effectiveness of foot orthoses in people with early RA.  We used the original Foot Function Index but 
a revised Foot Function Index has been reported to have good psychometric properties and is 
available in long and short forms for ease of clinical use [28]. Other specific foot instruments are 
currently available and further studies evaluating the most appropriate instrument to measure the 
cost-effectiveness of foot orthoses is warranted. 
 
CONCLUSION 
This exploratory trial was novel as it has undertaken the cost effectiveness evaluation of the use of 
customised foot orthoses and simple insoles in people with established RA. Future research should 
be undertaken to evaluate the cost effectiveness of these devices in large scale studies involving 
people with both newly diagnosed and established RA. This study will further inform health care 
professionals but may also stimulate discussion at higher levels and highlight the need for policy 
makers such as NICE to undertake Technology Appraisals and to further assess non-surgical 
interventions such as foot orthoses that are cost-effective. Future work should also include 
evaluating people’s acceptability of foot orthoses and their personal preferences. 
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Table 1: Descriptive statistics for the Foot Function Index domains  
Variables Custom Made Foot Orthoses  
Mean (SD) 
Simple Insoles  
Mean (SD) 
Foot Pain 
Baseline 
16 weeks 
 
54.2 (14.2) 
30.8 (22.1) 
 
54.7 (23.4) 
41.3 (17.9) 
Foot Disability 
Baseline 
16 weeks 
 
53.3 (21.5) 
38.8 (24.2) 
 
51.1 (19.0) 
44.2 (20.2) 
Functional Limitation  
Baseline 
16 weeks 
 
28.2 (25.3) 
22.8 (17.4) 
 
17.8 (11.8) 
17.4 (11.7) 
 
    
 
Table 2: Differences of Foot Function Index sub-domains from baseline to 16 weeks 
Variables Mean Difference between baseline and 16 
weeks (90%CI) 
P 
Foot Pain 
Custom Made Foot Orthoses  
Simple Insole  
Treatment effect  
 
-23.1 (-30.9 to -15.2) 
-12.9 (-21.0 to -4.8) 
-10.2 (-21.5 to 1.3) 
 
<0.000 
0.01 
0.14 
Foot Disability 
Custom Made Foot Orthoses  
Simple Insole  
Treatment effect  
 
-16.3 (-25.8 to -6.9) 
-3.9 (-12.9 to 5.2) 
-12.4 (-25.5 to 0.6) 
 
0.00 
0.40 
0.12 
Functional Limitation 
Custom Made Foot Orthoses 
Simple Insole  
Treatment effect 
 
-1.1 (-6.5 to 4.4) 
0.2 (6.4 to -6.8) 
-1.3 (-10.0 to -7.4) 
 
0.74 
0.95 
0.80 
 
 
  
 
 
Table 3: EQ5D utility index at baseline and 16 weeks  
Outcome Bootstrapped Mean 
(SD) 
Estimated Difference.  Adjusted for 
Baseline  (90% CI) 
P 
 Custom 
Made 
Foot 
Orthoses 
Simple 
Insole 
  
Baseline 
utility 
0.59 
(0.07) 
0.49 
(0.32) 
0.10 (-0.08 0.26)  0.34 
16 
Weeks 
utility 
0.57 
(0.28) 
0.56 
(0.22) 
0.01 (-0.15 0.14)  0.94 
QALY 0.04 
(0.10) 
0.00 
(0.10) 
 -0.03 (-0.08 0.03)  0.46 
 
 
 Table 4:  Mean NHS Resource Use 
Podiatrist Time Spent with 
Participant (minutes)  
Custom Made Foot Orthoses  
Mean (SD) 
Simple Insole 
Mean(SD) 
Time spent at baseline 24 (5) 23(7) 
Time spent at 16 weeks 20 (8) 20 (3) 
 
 Table 5:  Mean cost of resource use (£) over the 16 week follow-up period 
Resource Use Custom Made 
Foot Orthoses 
Mean (SD)  
Simple Insole 
Mean (SD)  
Mean difference (90% CI 
bootstrapped) 
Cost of intervention 33.35 (0) 24.82 (0) 8.53 (8.53,8.53) 
Total podiatrists time 33.25 (7) 32.78 (7) 0.46 (-3.54, 4.70) 
Total costs of 
equipment purchased 
by participants  
20.24 (47.46) 9.38 (25.30) 10.85 (-10.40, 35.79) 
Total costs of journeys 11.21 (9.52) 7.45 (6.15) 3.76 (-0.60, 8.77) 
Total Costs to 
participants 
31.45 (50.15) 16.86 (28.02) 14.62 (-8.27,40.53) 
Total Costs to the NHS 
(podiatrists time plus 
intervention cost) 
76.56 (7.07) 67.66 (6.75) 8.90 (4.78,13.39) 
Total costs to the NHS 
and participants 
108.01 (55.42) 84.50(29.30) 23.52(-1.67,50.94) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 1: CONSORT flow chart 
